EPA:GNFT Genfit (GNFT) Stock Price, News & Analysis €3.47 +0.20 (+6.04%) As of 07/23/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesBuy This Stock About Genfit Stock (EPA:GNFT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Genfit alerts:Sign Up Key Stats Today's Range€3.29▼€3.5150-Day Range€3.23▼€4.0552-Week Range N/AVolume311,724 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France. Read More Receive GNFT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genfit and its competitors with MarketBeat's FREE daily newsletter. Email Address GNFT Stock News HeadlinesGENFIT S.A.: June 17, 2025 Combined Shareholders Meeting ResultsJune 18, 2025 | finanznachrichten.deGENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen’s Iqirvo® in ItalyMay 21, 2025 | morningstar.comMGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthright” — a $150 trillion wealth vault that’s remained untouched for over a century. Jim Rickards believes President Trump is about to unleash it — and investors who move first could come out on top. The full story is now available.July 24 at 2:00 AM | Paradigm Press (Ad)European Equities Traded in the US as American Depositary Receipts Sharply Higher in Wednesday TradingApril 23, 2025 | msn.comGuggenheim Reaffirms Their Buy Rating on Genfit (GNFTF)March 31, 2025 | markets.businessinsider.comGENFIT S.A.: GENFIT Announces Completion of Non-dilutive Royalty Financing Agreement with HCRx and Results of Repurchase Offer to 2025 OCEANEs holdersMarch 21, 2025 | finanznachrichten.deEuropean Equities Traded in the US as American Depositary Receipts Surge Higher in Monday TradingMarch 3, 2025 | msn.comGenfit reports preliminary results of repurchase offer to 2025 OCEANEs holdersFebruary 21, 2025 | msn.comSee More Headlines GNFT Stock Analysis - Frequently Asked Questions How have GNFT shares performed this year? Genfit's stock was trading at €3.54 at the beginning of the year. Since then, GNFT shares have decreased by 1.7% and is now trading at €3.47. What other stocks do shareholders of Genfit own? Based on aggregate information from My MarketBeat watchlists, some other companies that Genfit investors own include Advanced Micro Devices (AMD), Alibaba Group (BABA), FedEx (FDX), GameStop (GME), NightHawk Biosciences (NHWK), United Parcel Service (UPS). Industry, Sector and Symbol Stock ExchangeEPA SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolEPA:GNFT CIKN/A Webwww.genfit.com Phone33 3 20 16 40 00FaxN/AEmployees120Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (EPA:GNFT) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredFREE GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...GoldCo Precious Metals | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredElon Musk: “This will transform civilization as we know it.”Robots are no longer science fiction — they’re the next trillion-dollar megatrend. According to Forbes, by ...Weiss Ratings | SponsoredWhy Elon put $51 million into thisEvery major AI breakthrough comes with a catch: It burns through power like jet fuel. Now Google, Microsof...True Market Insiders | SponsoredNew Federal Land Rush About to Start?A $100 Trillion Wealth Shift Is Already Underway Lithium. Oil. Gold. Trillions in U.S. resources are being ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genfit S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genfit With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.